Targeted Medical Pharma Forms Distribution Partnership with Cannabinoid Genetic Research Firm, ENDOCANNA Health

Los Angeles, February 6,  2019 – Targeted Medical Pharma (OTC: TRGM), today announced the completion of a distribution agreement with ENDOCANNA Health, a company that specializes in  personalized cannabis through a comprehensive Cannabinoid DNA Variant Test™.  

The Agreement is the first step in a multiyear partnership to improve personalized medicine by connecting clinical nutrition and the DNA variants that influence the endocannabinoid system to create effective and safer therapies for the long term management of chronic disease.  

Under the terms of the Agreement, ENDOCANNA Health has a three year nonexclusive right to the domestic distribution of the Company’s line of patented medical food products to include in their DNA Variant Testing program which is currently offered Nationwide by physicians and retailers.

“This partnership provides new opportunities for the research and development of novel therapies and clinical protocols capable of improving cannabinoid therapies for people suffering with chronic pain, anxiety, sleep disorders and obesity,” said Marcus Charuvastra, Managing Director of Targeted Medical Pharma. “Medical foods and phytocannabinoid therapies when used appropriately can have a very positive impact on nervous and endocannabinoid system health, restoring balance to systems that are degraded by disease, toxins, stress and genetics.”   

“Our partnership provides a unique opportunity to offer adjunct therapies that target multiple endogenous pathways simultaneously,” said Len May, CEO and co-founder of Endocanna Health. “By using Endocanna Health’s proprietary DNA report, we provide genetically-aligned protocols for clinicians to offer their patients along with analytical tools for clinical trials.” 

Connect with us on Twitter and Facebook.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the dietary management of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. 

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

####

Targeted Medical Pharma, Inc. Announces Q3 Financial Results and Clinical Program Updates

Los Angeles, CA, November 18, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development biotechnology company, today announced financial results for its third quarter ended September 30, 2014 and clinical trial updates.

The company reported significant improvement in both net loss and net loss before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis.
In Addition, in Q3, the company reported major advances in the development of new treatments for both chronic low back pain and Posttraumatic Stress Disorder, publishing new data for the products Theramine, Sentra AM and Sentra PM in The American Journal of Therapeutics and The Journal of Central Nervous System Disease respectively.

Management Comments

William Shell, M.D., Chief Executive Officer and Chief Science Officer of Targeted Medical Pharma, commented, “The gains in net loss and EBITDA in Q3 reflect our steadfast commitment to cost containment and continued focus on developing profitable business verticals.” He continued, “We made a lot of progress in the third quarter of 2014 with our product development and clinical data programs. Two papers were published in peer reviewed journals further validating the efficacy of the medical foods Theramine, Senta AM and Sentra PM helping to position these products for wider adoption by clinicians and consumers.”

A copy of Targeted Medical Pharma’s quarterly report on Form 10-Q for the three months ended September 30, 2014, filed with the Securities and Exchange Commission on November 14, 2014, is accessible on the Company’s website at www.tmedpharma.com and at the SEC’s website at www.sec.gov.

Financial Overview

Quarter-over-Quarter Comparison:

Financial results for the three months ended September 30, 2014 compared to the three months ended September 30, 2013.

  • Total revenue of $1.7 million, a 24% decrease from $2.2 million during the three months ended September 30, 2013.
  • Total gross profit of $1.2 million, a 25% decrease from $1.6 million during the three months ended September 30, 2013.
  • Adjusted EBITDA of ($0.3) million, a 73% improvement from $(1.1) million during the three months ended September 30, 2013.

Net loss for the three months ended September 30, 2014, was $1.0 million compared to a net loss of $1.7 million for the three months ended September 30, 2013. The Company’s operating expense for the third quarter of 2014 was $1.9 million, a 39% decrease from the third quarter of 2013.


About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that is committed to drug discovery and development. The company currently develops and distributes medications for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

For Updates, Follow the Company on Twitter @tmedpharma or on Facebook at www.facebook.com/TargetedMedicalPharma.

Forward Looking Statement

This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. Forward-looking statements also include any other passages that relate to expected future events or trends that can only be evaluated by events or trends that will occur in the future. The forward-looking statements are based on the opinions and estimates of management at the time the statements were made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. These risks and uncertainties include, among others, the risk of unforeseen changes in customer budgets, unanticipated loss of customers or delays in anticipated orders, the potential failure to attract new customers due to the company’s inability to competitively market its products and services, the risk of fluctuating demand for the company’s product, the potential failure to maintain desired customer relationships, costs and risks related to development of technologies. More information about factors that could cause actual results to differ materially from those predicted in Targeted Medical Pharma’s forward-looking statements is set out in its annual report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance upon these forward-looking statements, which speak only as to the date of this release. Except as required by law, Targeted Medical Pharma, undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise.

*Adjusted EBITDA refers to a financial measure that is more fully defined as net loss before net interest and other income, interest expense, income taxes, depreciation and amortization, and stock based compensation. Adjusted EBITDA is a non-GAAP financial measure which management believes reflects the Company’s ongoing business in a manner that allows for meaningful period-to-period comparisons and analysis of trends in the Company’s business, as they exclude certain income or other expenses that are not reflective of ongoing operating results. Adjusted EBITDA is commonly used to analyze companies on the basis of leverage and liquidity. However, Adjusted EBITDA is not a measure determined under GAAP in the United States of America and may not be comparable to similarly titled measures reported by other companies. Adjusted EBITDA should not be construed as a substitute for net loss or as a better measure of liquidity than cash flow from operating activities, which are determined in accordance with GAAP. Management believes that Adjusted EBITDA is a useful measure for analyzing operating results, and uses this non-GAAP financial measure to review past results and forecast future results.

 

####

Targeted Medical Pharma to Sponsor Clinical Trial Conducted by U.S. Army and Henry M. Jackson Foundation

Study to Examine the Use of Theramine for the Treatment of Acute or Sub-Acute Lower Back Pain due to Injury

Los Angeles, CA, July 28, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced the completion of an agreement to sponsor an investigator-initiated study with the United States Army and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF). The study, which is slated to start enrolling patients in Q2 of 2014, will involve the Company’s medical food Theramine.

The placebo-controlled study will seek to enroll 128 patients with acute or sub-acute lower back pain caused by injury. The principal investigator is an employee of the U.S. government and is the Director of Research, Department of Anesthesiology at Womack Army Medical Center Fort Bragg NC. The study is projected to be completed within 18 months from the first patient enrollment. Upon completion, the Foundation and the Principal Investigator will have the first opportunity to publish the results of the study whether or not the study results are favorable.

“We are excited to work with the HJF and the United States Army to further establish the efficacy of Theramine for the treatment of low back pain,” said William Shell M.D., Chief Executive Officer and Chief Science Officer at Targeted Medical Pharma. “Theramine has previously been established in two double-blind, multi-center trials to be effective at improving chronic low back pain, and has been in clinical use for over a decade. Sponsoring this trial provides our Company with a unique opportunity to service the men and women of the United States Military, providing them a safe and non-addictive option for pain management.”

About The Henry M. Jackson Foundation for the Advancement of Military Medicine

The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. is a global organization dedicated to advancing military medical research. The Foundation serves military, medical, academic and government clients by administering, managing and supporting preeminent scientific programs that benefit members of the armed forces and civilians alike.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #

Targeted Medical Pharma to Present at 2013 Southern California Investor Conference

Los Angeles, CA, August 6th, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies for the treatment of chronic disease, today announced that the company’s CEO and Chief Science Officer William Shell, M.D., will be presenting at the 2013 Southern California Investor Conference being held at the Island Hotel in Newport Beach, California on Thursday, August 8, 2013 at 8:30 a.m. PST.

Interested parties may listen to the presentation through a live audio webcast available at californiastocks.com. Listeners are encouraged to visit the website at least 15 minutes prior to the start of the scheduled presentation. A copy of the presentation also can be found by visiting the events and presentation section within the investor relations portion of Targeted Medical Pharma’s website or by clicking here.

According to a recent research report by Falls Church, VA-based Technology Catalysts International, the global medical foods market is estimated at approximately $12 billion and growing.  The report notes that consumer and scientific interest in the relationship between diet, health, and alternative medicines has created an increased demand for medical foods.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods  for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders.  The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical.  These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.

 

#   #   #

Targeted Medical Pharma Reports 2013 First Quarter Results

— Company Reports Record Revenue through Continued Execution of Growth Plan —

Los Angeles, May 15, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), a biotechnology company that develops and distributes prescription medical foods, convenience kits and generic pharmaceuticals to physicians and pharmacies, today announced financial results for its first quarter ended March 31, 2013. The Company posted record quarterly revenue of $2.811 million for the first quarter ended March 31, 2013, compared to revenue of $1.375 million for the first quarter ended March 31, 2012, an increase of 104.4 percent.

“I am thrilled to report the Company’s strongest recorded quarterly revenue as we continue to execute on our growth strategy,” commented William Shell, M.D., Chief Executive Officer and Chief Science Officer of Targeted Medical Pharma. “The expansion and application of current initiatives, and our ability to enter new markets, has resulted in increased revenue for all of our business lines, and helped us generate our fifth consecutive quarter of revenue growth. The actual growth in revenue was over one-hundred percent in the first quarter of 2013, compared to the first quarter of 2012, and we were cash flow positive from operations as well. I am optimistic about our growth and the team we have in place as we continue to strengthen our product pipeline and expand our sales and marketing efforts, while at the same time contain our operating expenses as we work to expand market share and enter new markets. I am also very encouraged with the expansion of our product line to support the needs of our customers.”

Financial Overview: 
Revenues for the three months ended March 31, 2013 were $2.811 million, compared to $1.375 million for the three months ended March 31, 2012, an increase of $1.436 million, or 104.4 percent. The increase in revenue was primarily attributed to a significant increase in prescriptions among workers compensation and commercial providers, along with improved collection rates for new and aged receivables.

Gross profit for the three months ended March 31, 2013 was $1.912 million, compared to $0.740 million for the three months ended March 31, 2012, an increase of $1.172 million, or 158.3 percent. The increase in gross profit was attributed to increased revenues resulting from a significant increase in collections and to a lesser extent payments associated with the Cambridge contract.

The net loss for the three months ended March 31, 2013 was $0.270 million and the diluted loss per share was $0.01, compared to a net loss of $0.976 million and diluted loss per share of $0.04 for the same period in 2012. The decrease in net loss was attributed to higher revenue combined with modest growth in operating expenses.

As of March 31, 2013 the Company had $34.6 million of unrecognized accounts receivables, not on the balance sheet due to our policy of not recognizing revenue for delivered product with a long collection cycle, until the cash is received. This unrecognized asset has the potential to become revenue in the future as the Company’s billing and collection subsidiary continues to collect accounts receivable on behalf of physicians using the Company’s managed business model and hybrid business model, for patient claims.

Adjusted EBITDA, a non-GAAP measure set forth in the table below, was negative $117 thousand for the three month period ended March 31, 2013, compared to negative $1.284 million for the three month period ended March 31, 2012, which is a reduction of $1.167 million or 91 percent.

“We’re very pleased to have generated positive cash flow from operations during the quarter,” said David Silver, M.D., President and Chief Operating Officer of Targeted Medical Pharma. “The results from the Cambridge agreement initiated in the first quarter of 2013, as well as our cost containment efforts, have established a good cash flow trajectory for the Company. We are focused on improving our margins and continue to leverage efficiencies in our distribution models, both of which contributed to a 68 percent operating loss improvement, as compared to the first quarter of 2012. We continue to build brand recognition in the medical community and are seeing increased demand from patients seeking our prescription medical foods. As we move forward with continued development of new products, we will remain focused on sustaining the growth reported for the first quarter.”

First Quarter Highlights:

  • Expansion of private insurance market business
  • Expansion of California Worker’s Compensation market business
  • Issuance of our billing patent related to point of care medication dispensing and billing
  • Submission of four new patent applications related to the oral stimulation of stem cells, particularly for the oral stimulation of progenitor red blood cell stem cells for treatment of chronic anemia
  • Expansion of Agreement with Cambridge Medical Funding
  • On April 19, 2013 the Company’s Registration Statement on Form S-1/A which registers up to 25,723,395 shares of common stock for resale was declared effective. The registration only involved existing shares and no new shares were issued. Of the 25,723,395 shares, 14,590,065 shares are owned by Company Insiders subject to Rule 144

Continued 2013 Strategic Initiatives:

  • Expansion of sales and marketing efforts to increase prescribing in the Workers’ Compensation and private insurance markets
  • Conduct additional clinical trials for current and pipeline products including Theramine®, and new formulas for red blood cell production and nasal decongestion.
  • Continue development of new stem cell products for neuropathy, chronic anemia, and diabetes

Detailed financial data information is available on Targeted Medical Pharma’s annual report (Form 10-Q), which is accessible on the Company’s website at www.tmedpharma.com and on the SEC’s website at sec.gov/edgar.shtml.

About Targeted Medical Pharma, Inc. 
Targeted Medical Pharma is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures 10 proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the United States through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I. Targeted Medical Pharma also provides a billing and collection services on behalf of dispensing physicians.

Reasons for Presentation of Non-GAAP Financial Measures
Statements made in this release include a non-GAAP financial measure. Such information is provided as additional information, not as an alternative to our consolidated financial statements presented in accordance with GAAP, and is intended to enhance an overall understanding of our current financial performance. We believe the non-GAAP financial measure provides useful information to management, investors and prospective investors by excluding certain charges and other amounts that we believe are not indicative of our core operating results. The non-GAAP measure is included to provide management, our investors and prospective investors with an alternative method for assessing our operating results in a manner that is focused on the performance of our ongoing operations and to provide a more consistent basis for comparison between quarters. The non-GAAP financial measure presented is Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, derivative revaluation, stock option compensation expense and stock issued for services). This term might not be calculated in the same manner as, and thus might not be comparable to, similarly titled measures reported by other companies. The financial statement tables that accompany this press release include reconciliation of the non-GAAP financial measure to the most directly comparable GAAP financial measure.


Forward Looking Statement 
This press release may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Theramine® is a trademark of Targeted Medical Pharma Inc.

Click here to download press release.

# # #

gfx_summary_consolidatet_stmt_of_loss

Targeted Medical Pharma Reports New Data on Red Blood Cell Stimulating Formulation

Los Angeles, March 4, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today unveiled new results from an open label study of its oral amino acid-based erythrocyte stimulating system (ESS) for the treatment of chronic anemia. The company’s ESS system is designed to stimulate progenitor stem cells in the bone marrow.

Subjects in the study diagnosed with mild to moderate anemia were administered 1800mg of the company’s oral formulation daily for seven days. Each subject underwent weekly blood sampling, including hemoglobin, hematocrit and reticulocyte count for four weeks from the initial dosing, and once more 45 days following the initial dose. Hemoglobin increased an average of 11.39 percent from baseline measurement to 45 days. The average baseline hemoglobin measurement was 10.08 and 11.21 after 45 days with a similar increase in reticulocyte count (p<0.01).

“This is the first demonstration that an oral stimulation of progenitor red blood cells with a targeted amino acid therapy can initiate progenitor stem cell conversion of undifferentiated red blood cells to mature red blood cells with an increase in hemoglobin content in patients with chronic anemia,” said William Shell, M.D., CEO of Targeted Medical Pharma, Inc. “Developing an oral system for stimulating mature blood cells from progenitor cells is a milestone for our company and may represent a method to modulate red blood cell function in patients with anemia.”

Preliminary results of the study released last year also found a 16 percent increase in hemoglobin and a 450 percent increase in peripheral reticulocytes over a seven day period (p<0.01) among normal volunteers taking ESS. The company plans to perform further testing of its red blood cell stimulating system and to explore treatment applications in other forms of anemia.

About Targeted Medical Pharma, Inc. 

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease including pain syndromes, peripheral
neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures ten proprietary prescription only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.

Forward Looking Statement 

This press release regarding data results of an investigational study of a new formulation affecting the hemopoetic system may contain forward-looking statements related to the company’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Click here to download press release.

# # #

Targeted Medical Pharma is Assigned Comprehensive Pharmaceutical Billing Patent

Los Angeles, February 12, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced it has been issued patent number 8370172 from the United States Patent and Trademark Office. This is the company’s seventh patent and relates to a system and method for electronically submitting medication claims by point-of-care physicians. The patent officially was issued on February 5, 2013.

“The issuance of this billing patent creates an opportunity for our company and we anticipate that this patent will help increase our revenue, spur development, and provide a powerful tool for our customers,” said William Shell, M.D., inventor of the patent, CEO and chief scientific officer at Targeted Medical Pharma, Inc.

More information on patent number 8370172 can be found by visiting http://bit.ly/TRGMPatent5 or clicking here.

About Targeted Medical Pharma, Inc. 

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures ten proprietary prescription only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.

Forward Looking Statement 

This press release regarding patent number 8370172 may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Click here to download press release.

# # #

Targeted Medical Pharma Receives Notice of Issuance for Comprehensive Billing Patent

Los Angeles, January 30, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) regarding projected patent number 8370172, which relates to a system and method for submitting claims for a dispensed medication to a patient by point-of-care physicians. The USPTO indicated that it expects the patent will be issued on February 5th, 2013.

“The issuance of this patent further establishes our leadership position in the medical reimbursement arena at a time when electronic billing is growing among physicians in clinical practice,” said William Shell, M.D., co-inventor of the patent, CEO and chief scientific officer at Targeted Medical Pharma, Inc. “This patent provides point of care physicians with a powerful tool to bill for medications utilized within their practices.”

Visit http://bit.ly/TargetedMedicalPharmaUSPTOPatent or click here for more information regarding the patent.

About Targeted Medical Pharma, Inc. 

Targeted Medical Pharma, Inc. is a Los Angeles-based is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures ten proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. and the Middle East through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.

Forward Looking Statement 

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #

Five Targeted Medical Pharma Products Listed on U.S. Dept. of Veterans Affairs’ Federal Supply Schedule (FSS)

–Company’s Prescription-Only Medical Foods Now Available for Purchase by Federal Agencies through FSS–

Los Angeles, January 7, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a biotechnology company that develops and distributes prescription medical foods to physicians and pharmacies, today announced that five of its core prescription-only medical foods are now listed on the U.S. Department of Veterans Affairs’ Federal Supply Schedule (FSS).

The Company’s designated products are listed under the FSS category 65IB: Drugs, Pharmaceuticals and Hematology products. The listed products that are now available for purchase by federal agencies include AppTrim®, Theramine®, GABAdone® , Sentra AM® and Sentra PM®.

“Inclusion of our Company’s proprietary medications on the Federal Supply Schedule provides Military and Veteran healthcare providers access to effective and safe prescription medications that can greatly improve patient clinical outcomes without harmful side effects,” said Dr. William E. Shell, CEO of Targeted Medical Pharma. “The FSS award provides our Company with the unique opportunity to service the nation’s federal agencies, providing them with safer, more effective pharmacologic options for disease management and prevention.”

The FSS listing of the Company’s products became effective with a contract award by the Department of Veterans Affairs to N3 Technologies, Inc., a Service-Disabled Veteran-Owned Small Business (SDVOSB), which is the contracted distributor to federal agencies for Targeted Medical Pharma. The FSS contract, V797D-30064, is effective through December 14, 2017.

About Targeted Medical Pharma, Inc. 

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures ten proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the U.S. and the Middle East through the company’s division, Physician Therapeutics, These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Targeted Medical Pharma also provides diagnostic testing as well as billing and collection services on behalf of dispensing physicians.

Forward Looking Statement 

This press release may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “believe,” “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based. 

# # #

Targeted Medical Pharma Signs Agreement to Assign Certain Accounts Receivables to Cambridge Medical Funding Group

Los Angeles, November 27, 2012Targeted Medical Pharma, Inc. (OTCQB: TRGM) (OTCBB: TRGM), a specialty pharmaceutical company that develops and sells prescription medical foods to physicians and pharmacies for the treatment of chronic disease, today reported the completion of an agreement under which certain accounts receivables will be assigned to New Jersey-based Cambridge Medical Funding Group, LLC (CMFG).

Under the terms of the agreement, medical providers who purchase products from Targeted Medical Pharma will have the option to assign certain accounts receivables from California Workers’ Compensation benefit claims to CMFG at a discounted rate.

“This agreement permits Targeted Medical Pharma to more quickly collect outstanding amounts owed to the company by physicians who will purchase our products, providing us with more opportunities to accelerate growth because of the improved time-to-collection,” said William Shell, M.D., CEO of Targeted Medical Pharma. “Physicians also will benefit from the reduced time spent on the billing and collection process and avoid lengthy delays in workers’ compensation payer reimbursements.”

About Cambridge Medical Funding Group, LLC

Based in Glen Rock, New Jersey, Cambridge Medical Funding Group provides specialized finance solutions to hospitals, surgical centers and medical providers, purchasing receivables and providing guaranteed upfront payments to these providers.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells prescription medical foods to physicians and pharmacies for the treatment of chronic disease, including pain syndromes, obesity, sleep and cognitive disorders. The company manufactures nine proprietary prescription-only medical foods, as well as 48 convenience packed kits, which pair a medical food and branded or generic pharmaceutical. These prescription medical food products and therapeutic systems represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. Based in Los Angeles, the company’s proprietary pharmaceutical therapeutic systems are currently sold in the United States, Japan, and the Middle East. Targeted Medical Pharma also provides billing and collection services on behalf of dispensing physicians.

Forward Looking Statement

This press release about an agreement with Medical Funding Group, LLC may contain forward-looking statements related to Targeted Medical Pharma’s business strategy, outlook, objectives, plans, intentions or goals. The words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaim any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

# # #